Companies › Kiora Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 2; Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KIO-104 Dihydroorotate dehydrogenase (DHODH) inhibitor | DHODH | Phase 2 | Macular Edema | Nov 2026 |
| KIO-301 KIO-300 quaternary ammonium salt | – | Phase 2 | Retinitis Pigmentosa | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06825702 | KIO-104 | Phase 2 | Macular Edema | Ophthalmology | Nov 2026 |
| NCT06628947 | KIO-301 | Phase 2 | Retinitis Pigmentosa | Ophthalmology | Aug 2027 |
Cash and short-term investments of $17m on 2026-06-30; operating cash outflow about $10m a year; runway about 20 months at that burn, to Feb 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Caravel Oculus
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.